Physician profile
Christopher Inclima
NPI 1063474575
$3,586.14
in general payments reported to CMS, 2019-2025
22 companies · $569 in 2025
The $569 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $284 · 2021: $392 · 2022: $740 · 2023: $534 · 2024: $612 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,714.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $816.49 | 2020-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $496.19 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $435.13 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $400.79 | 2019-2025 | Rocklatan, Simbrinza, Rhopressa |
| Tarsus Pharmaceuticals, INC. | $229.56 | 2024-2025 | Xdemvy |
| Allergan, INC. | $208.02 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $178.16 | 2019-2021 | |
| Glaukos Corporation | $139.68 | 2024 | Idose |
| Spark Therapeutics, INC. | $125.00 | 2022 | |
| Oyster Point Pharma, INC. | $103.27 | 2022-2025 | Tyrvaya |
| Maculogix, INC. | $95.57 | 2019 | |
| Kala Pharmaceuticals, INC. | $72.54 | 2021 | |
| Novartis Pharmaceuticals Corporation | $66.77 | 2021-2023 | |
| Coopervision INC. | $41.48 | 2021-2022 | |
| Harrow Eye, LLC | $40.84 | 2025 | Vevye |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visioneering Technologies, INC. | $30.30 | 2019-2020 | |
| Abbvie INC. | $25.00 | 2024 | |
| Dompe US, INC. | $20.45 | 2022 | |
| Eyevance Pharmaceuticals LLC | $17.23 | 2023 | Flarex |
| Shire North American Group INC | $15.63 | 2019 | |
| Thea Pharma INC. | $15.38 | 2023 | |
| Sight Sciences, INC. | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Inclima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.